Research · Sep 3, 2026
[KRYS] Krystal Biotech Thesis 2026: Vyjuvek Topical Gene Therapy Drives DEB Commercial Capital Return
Krystal Biotech, Inc. (NASDAQ: KRYS) FY2025 revenue ~$380-440M (+80-110%) with adj. EPS ~$4.50-5.40 reflecting continued post-May 2023 Vyjuvek FDA approval ~$380-440M aggregate Vyjuvek Topical Gene Therapy revenue (~$350-410M aggregate US Vyjuvek + ~$30-35M aggregate ex-US launches) under continued Co-Founder + CEO Krish Krishnan since 2017 (~8-year founding tenure as Krystal Biotech CEO). One of the largest US specialty commercial-stage gene therapy biotech companies. Founded April 2016 as Krystal Biotech by Krish Krishnan + Suma Krishnan in Pittsburgh Pennsylvania (~9-year heritage; selected pioneer Topical Gene Therapy using HSV-1 vector platform); selected post-September 2017 NASDAQ IPO ($32M IPO proceeds); selected post-2017-2025 ~$1.2B+ cumulative equity raises; selected post-May 2023 Vyjuvek FDA approval (1st FDA-approved topical gene therapy + 1st FDA-approved DEB treatment); selected post-April 2024 EU EMA Vyjuvek approval; selected post-2025 Japan PMDA Vyjuvek approval expected. Headquartered in Pittsburgh Pennsylvania; ~400-450 employees globally with ~15-20% Krish + Suma Krishnan + Foundation Asset Management + institutional ownership concentration. One primary business: commercial-stage gene therapy biotech ~100%. Structure: Vyjuvek Topical Gene Therapy ~100% ($380-440M). Geographic mix: US ~92%+ + EU + Japan + Korea + international ~8%. Vyjuvek Topical Gene Therapy pipeline (~$380-440M revenue + 1st-in-class): ~$380-440M aggregate Vyjuvek revenue (~100% revenue mix); selected primary post-May 2023 FDA approval (1st FDA-approved topical gene therapy + 1st FDA-approved DEB treatment); selected ~3,000-3,500+ US DEB patient addressable population; selected ~$0.5-1.0M annual cost per DEB patient; selected ~50-65% US Vyjuvek penetration rate; selected post-April 2024 EU EMA approval; selected post-2025 Japan PMDA approval expected. KB407 + KB408 + KB801 + Pipeline + Ex-US Launches: selected continued post-2024 KB407 (CF Phase 1) + KB408 (AATD Phase 1) + KB801 (Neurotrophic Keratitis Phase 1/2) + KB104 (Netherton Syndrome Phase 1/2) + KB707 (immunotherapy oncology Phase 1); selected Europe + Japan + Korea + Brazil + international Vyjuvek launches; selected Vyjuvek Pediatric label expansion. Co-Founder + CEO Krish Krishnan since 2017 (~8-year founding tenure; co-founder Suma Krishnan President R&D); CFO Kathryn Romano. Capital position: ~$0 dividend (no dividend track post-September 2017 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025; net cash ~$0.7-0.9B aggregate cash + investments balance; net leverage ~negligible (~debt-light); investment-grade Baa3/BBB- credit rating (post-Vyjuvek commercial); ~28-30M diluted shares. FY2026 thesis: Vyjuvek US commercial expansion (50-65% → 65-75%) + Vyjuvek ex-US launches (EU + Japan + Korea + Brazil) + KB407 + KB408 + KB801 + KB104 + KB707 pipeline + ~$0.5-1.0M annual cost per DEB patient + ~$0.7-0.9B aggregate cash runway + ~50-80% aggregate revenue growth + ~$1.0-1.5B FY2026 revenue potential. Risks: BridgeBio Pharma + BioMarin Pharmaceutical (Roctavian) + Sarepta Therapeutics + Abeona Therapeutics + Castle Creek Biosciences (post-2024 IPO DEB Photobiotic competitor) + Vertex Pharmaceuticals (CF) + Pfizer competitive displacement + Centene Magellan Rx + Express Scripts + CVS Caremark payer reimbursement cycle considerations + Vyjuvek IP defense considerations + post-April 2024 EU EMA launch execution considerations + post-2025 Japan PMDA approval timing considerations + Krystal Biotech HSV-1 vector platform IP defense considerations + post-2017 Krish + Suma Krishnan founder concentration governance considerations.